A Common 4G Allele in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene as a Risk Factor for Pulmonary Embolism and Arterial Thrombosis in Hereditary Protein S Deficiency

Bengt Zöller; Pablo García de Frutos; Björn Dahlbäck

doi:10.1055/s-0037-1615068

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 79(04): 802-807
DOI: 10.1055/s-0037-1615068

Rapid Communication

Schattauer GmbH

A Common 4G Allele in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene as a Risk Factor for Pulmonary Embolism and Arterial Thrombosis in Hereditary Protein S Deficiency

Autor*innen

Bengt Zöller¹
Pablo García de Frutos

¹From the Department of Clinical Chemistry, Malmö University Hospital, Lund University, Sweden
Björn Dahlbäck

¹From the Department of Clinical Chemistry, Malmö University Hospital, Lund University, Sweden

Abstract

Summary

Reduced fibrinolytic capacity due to increased plasminogen activator inhibitor-1 (PAI-1) activity in plasma is a common finding in patients with coronary heart disease or venous thromboembolism, although its clinical significance is debated. Recently, a dimorphism in the PAI-1 promoter (4G-5G) has been reported and homozygosity for the 4G allele is associated with increased transcription and higher PAI-1 levels. Homozygous 4G genotype has been suggested to be a risk factor for myocardial infarction. In the present study, the 4G-5G dimorphism was determined in 349 individuals from 21 thrombophilic families with hereditary protein S deficiency and in 140 unrelated healthy controls. Among the 143 protein S deficient individuals, there was no relationship between deep or superficial venous thrombosis and the PAI-1 dimorphism. However, 26% (12/46) of individuals having protein S deficiency combined with homozygosity for the 4G allele had suffered pulmonary embolism as compared to 7% (7/97) of protein S deficient individuals carrying at least one 5G allele (p = 0.0019). In protein S deficient individuals, arterial thrombosis was found to be associated with smoking and 4G homozygosity. No association was found between the PAI-1 dimorphism and arterial or venous thromboembolism in family members without protein S deficiency. In conclusion, the PAI-1 genotype affects the phenotypic expression of thrombophilia in protein S deficient individuals.

Volltext

Referenzen

References
1 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
2 Dahlbäck B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43.
3 Engesser L, Broekmans AW, Briët E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: Clinical manifestations. Ann Intern Med 1987; 106: 677-82.
4 Zöller B, García de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85: 3524-31.
5 Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
6 Koster T, Rosendaal FR, Briët E, Vandermeer FJM, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 1995; 85: 2756-61.
7 Koeleman BPC, Reitsma PH, Allaart RC, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
8 Koeleman BPC, van Rumpf D, Hamulyák K, Reitsma PH, Bertina RM. Factor V Leiden. An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-3.
9 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV:R⁵⁰⁶Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21.
10 Mannucci PM, Tripodi A, Bertina RM. Protein S deficiency associated with “juvenile” arterial and venous thrombosis. Thromb Haemost 1986; 55: 440.
11 Coller BS, Owen J, Jesty J, Horowitz D, Reitman MJ, Spear J, Yeh T, Comp PC. Deficiency of plasma protein S, protein C, or antithrombin III and arterial thrombosis. Arteriosclerosis 1987; 7: 456-62.
12 Israels SJ, Seshia SS. Childhood stroke associated with protein C or S deficiency. J Pediatr 1987; 111: 562-4.
13 Girolami A, Simioni P, Lazzaro AR, Cordiano I. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): a family study. Thromb Haemost 1989; 61: 144-7.
14 Allaart RC, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina RM, Briët E. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990; 64: 206-10.
15 Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology 1992; 42: 1029-33.
16 Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-6.
17 Wiman B, Ljungberg B, Chmielewska J, Urdén G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-70.
18 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
19 Chakrabarti R, Hocking E, Fearnly GR, Mann RD, Atwell TN, Jackson D. Fibrinolytic activity and coronary-artery disease. Lancet 1968; 56: 987-90.
20 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
21 Aznar J, Estellés A, Tormo G, Sapena P, Tormo V, Blanch S, España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-41.
22 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
23 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
24 Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 1978; 203: 477-80.
25 Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VII/von Willebrand´s factor. Am J Med 1983; 74: 33-9.
26 Jörgensen M, Mortensen JZ, Madsen AG, Thorsen S, Jacobsen B. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis. Scand J Haematol 1982; 29: 217-23.
27 Nilsson IM, Tengborn L. Impaired fibrinolysis. New evidence in realation to thrombosis. in Jespersen J, Kluft C, Korsgaard O. (eds) Clinical aspects of fibrinolysis and thrombolysis. Proceedings of the international symposium 9-10 september 1983, Esbjerg, Denmark, in the honour of Dr. Tage Astrup. South Jutland University Press; 1983: 273-291.
28 Pizzo SV, Fuchs HE, Doman KA, Petruska DB, Berger H. Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. Arch Intern Med 1986; 146: 188-91.
29 Jörgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Brit J Haematol 1987; 65: 175-80.
30 Zöller B, Dahlbäck B. Protein S deficiency in a large family with thrombo philia previously characterized as having an inherited fibrinolytic defect. Thromb Haemost 1993; 69: 1256.
31 Bolan CD, Krishnamurti C, Tang DB, Carrington LR, Alving BM. Association of protein S deficiency with thrombosis in a large kindred with increased levels of plasminogen activator inhibitor-1. Ann Intern Med 1993; 119: 779-85.
32 Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease – critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
33 Engesser L, Brommer EJP, Kluft C, Briët E. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? – A study of 203 patients with familial or sporadic venous thrombophilia. Thromb Haemost 1989; 62: 673-80.
34 Takada A, Takada Y, Urano T. The physiological aspects of fibrinolysis. Thromb Res 1994; 76: 1-31.
35 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
36 Eriksson P, Kallin B, van’t Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
37 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
38 Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-7.
39 Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-4.
40 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
41 Simmonds RE, Zöller B, Ireland H, Thompson E, García de Frutos P, Dahlbäck B, Lane DA. Genetic and phenotypic analysis of a large (122 member) protein S-deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89: 4364-70.
42 García de Frutos P, Alim RIM, Härdig Y, Zöller B, Dahlbäck B. Differen tial regulation of α and β chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-22.
43 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
44 Scott BD, Esmon CT, Comp PC. The natural anticoagulant protein S is decreased in male smokers. Am Heart J 1991; 122: 76.
45 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
46 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-6.
47 Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 1996; 84: 431-43.
48 Yamada N, Wada H, Nakase T, Minamikawa K, Nagaya S, Nakamura M, Hiraoka N, Fuzioka H, Hayashi T, Suzuki K. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis. Blood Coagul Fibrin 1995; 6: 627-33.
49 Huisman MV, Buller HR, ten Cate JW, van Royen EA, Vreeken J, Kersten MJ, Bakx R. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95: 498-502.
50 Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: A randomized trial. Ann Int Med 1987; 107: 441-5.
51 Thomas DP. Pathogenesis of venous thrombosis. in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds) Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone; 1994: 1335-47.
52 Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-21.
53 Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996; 76: 510-7.
54 Martinelli I, Catanneo M, Panzeri D, Mannucci PM. Low prevalence of factor V:Q⁵⁰⁶ in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-3.
55 Desmarais S, de Moerloose P, Reber G, Minazio A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.